Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
May 15, 2005 (Vol. 25, No. 10)

The Cancer Information Network

  • Useful general information
  • Not aimed at scientists
My dinner was long digested when I saw the opening page of this site with the picture rather ugly cancerous tissue, but I still had my stomach turn at the site of it. It's hard to image a more effective way to drive users from your page than to use images that are "not pretty." That's unfortunate, because most of the rest of the items on this page are interesting, informative, and worth spending time on. The opening page also has short summaries with links to news sites on various cancer findings ("Calcium More Protective Against Some Polyps"), general information ("What Do You Need To Know About Cancer?:), and potential treatments (Clinical Trials). Mostly aimed to patients and their families, The Cancer Information Network is an informative site on an important topic. Now if they could just change that opening image...
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »